- Home
- GILT vs PHAT Comparison
GILT vs PHAT Comparison
Compare GILT & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILT
- PHAT
- Stock Information
- Founded
- GILT 1987
- PHAT 2018
- Country
- GILT Israel
- PHAT United States
- Employees
- GILT N/A
- PHAT N/A
- Industry
- GILT Radio And Television Broadcasting And Communications Equipment
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- GILT Technology
- PHAT Health Care
- Exchange
- GILT Nasdaq
- PHAT Nasdaq
- Market Cap
- GILT 797.0M
- PHAT 942.6M
- IPO Year
- GILT 1993
- PHAT 2019
- Fundamental
- Price
- GILT $13.45
- PHAT $14.60
- Analyst Decision
- GILT Strong Buy
- PHAT Strong Buy
- Analyst Count
- GILT 1
- PHAT 5
- Target Price
- GILT $11.00
- PHAT $17.60
- AVG Volume (30 Days)
- GILT 825.0K
- PHAT 1.0M
- Earning Date
- GILT 11-12-2025
- PHAT 10-30-2025
- Dividend Yield
- GILT N/A
- PHAT N/A
- EPS Growth
- GILT 42.22
- PHAT N/A
- EPS
- GILT 0.41
- PHAT N/A
- Revenue
- GILT $392,826,000.00
- PHAT $147,190,000.00
- Revenue This Year
- GILT $47.18
- PHAT $218.38
- Revenue Next Year
- GILT $13.80
- PHAT $87.14
- P/E Ratio
- GILT $31.76
- PHAT N/A
- Revenue Growth
- GILT 29.68
- PHAT 460.30
- 52 Week Low
- GILT $4.86
- PHAT $2.21
- 52 Week High
- GILT $15.24
- PHAT $17.63
- Technical
- Relative Strength Index (RSI)
- GILT 50.95
- PHAT 66.47
- Support Level
- GILT $12.27
- PHAT $12.31
- Resistance Level
- GILT $14.58
- PHAT $14.22
- Average True Range (ATR)
- GILT 0.57
- PHAT 0.98
- MACD
- GILT -0.23
- PHAT 0.03
- Stochastic Oscillator
- GILT 43.53
- PHAT 60.74
About GILT Gilat Satellite Networks Ltd.
Gilat Satellite Networks Ltd is a provider of satellite-based broadband communications. The company designs and manufactures ground-based satellite communications equipment and provides comprehensive solutions and end-to-end services. Its portfolio includes a cloud-based satellite network platform, very small aperture terminals (VSATs), amplifiers, high-speed modems, on-the-move antennas and high-power solid-state power amplifiers (SSPAs), block-up converters (BUCs), and Transceivers. The company's solutions support multiple applications with a full portfolio of products to address key applications including broadband access, cellular backhaul, enterprise, in-flight connectivity, maritime, trains, defense, and public safety.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.